Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

Also called NCT07374328

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07374328
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07374328. Randomized; single masking; primary purpose treatment. Start 2025-06-01 (actual); primary completion 2026-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus
Acronym
TRED
Intervention (Drug)
Semaglutide (1 Mg Dose)
Intervention (Drug)
Sitagliptin (DPP4 inhibitor)
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University (class: other)

Record details

Record id
cardio:ct-nct07374328
Content hash
e504bba4855f21d992e85aa101c879f994ab77e85449187064d0eb115d4c6c02